Question · asked by 1 review
Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo: Overall survival
- Population
- Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
- Intervention
- Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous
- Comparison
- placebo
- Outcome
- Overall survival
Palifermin showed no clear difference in overall survival compared with placebo (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Palifermin vs Placebo Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region · 42 to 72 months from baseline Palifermin showed no clear difference in overall survival compared with placebo (moderate certainty). Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy (2017) · Cochrane All outcomes | HR 1.00 [0.72, 1.39] | 3 studies | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes | 2016-09 | Not listed | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.